Navigation Links
Eliminating Barriers to Treatment for Patients with HCV Who Inject Drugs
Date:11/15/2015

SAN FRANCISCO, Nov. 15, 2015 /PRNewswire/ -- Injection drug use is a major risk factor for transmission of hepatitis C virus (HCV). In May 2015, the Centers for Disease Control reported that acute HCV infection in three Appalachian states rose by 364 percent among people under 30 years old, and 73 percent of those asked had used intravenous drugs.

According to a presentation by Gregory Dore, MD, at the annual meeting of the American Association for the Study of Liver Diseases, very little data are available on interferon-free treatment of patients who have HCV and who use drugs. When asked why, Dr. Dore replied, "There has been concern that people who use illicit drugs will not be adherent with new HCV therapies or outcomes would be poorer in more marginalized populations."

For this placebo-controlled, randomized study, antiviral therapy using Grazoprevir and Elbasvir in an all-oral, once-daily, one-pill regimen was highly effective and well-tolerated. All patients had chronic HCV and were on opiate agonist therapy of either methadone or buprenorphine. Patients with cirrhosis and/or HIV were eligible, with 301 subjects randomized to immediately receive therapy (n=201) or placebo followed by active study therapy (n=100).

Researchers found that although 79 percent of those in the immediate therapy group used drugs during the 12 weeks of therapy, 99 percent of them completed the therapy and 95 percent achieved sustained virologic response (SVR). There were five subjects who developed HCV reinfection following treatment, and if considered as failures the SVR is 92%. There was also no significant difference in adverse events between the active and placebo groups.

While acknowledging that these data are preliminary, researchers concluded this therapy regimen is safe and highly effective and supports efforts to address to barriers to treatment for patients with HCV who use drugs. According to Dr. Dore, "The CO-STAR study is the first phase III evaluation of interferon-free and ribavirin-free therapy in a population on drug dependency treatment, most of whom had ongoing illicit drug use. The safety and high efficacy convincingly demonstrate the benefits of treating HCV within this population. Such evidence should enhance access to new HCV therapies, including removal of restrictions to access in many settings based on illicit drug use."

When asked about the significance of these results, Dr. Dore responded, "CO-STAR demonstrates that Elbasvir/Grazoprevir can successfully treat patients with chronic HCV infection on opiate agonist therapy who may also be using illicit drugs.  There is high efficacy which shows that this patient population took their medication as prescribed. This study offers reassurance to providers who are concerned that patients who actively use illicit drugs will not be adherent to their chronic HCV treatment. This comprehensive study indicates that these patients could adhere to this once-daily, single-tablet regimen as much as patients who are not actively using illicit drugs."

"The CO-STAR study provides even more support for treating patients with chronic HCV infection on opiate agonist therapy, thus reducing individual-level disease burden in this population and providing potential reduction in HCV transmission," concluded Dr. Dore.

Abstract title: C-EDGE CO-STAR: efficacy of grazoprevir/elbasvir fixed dose combination for 12 weeks in HCV-infected persons who inject drugs on opioid agonist therapy

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, CA, November 14-17, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 13 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

Media Contact: Gregory Bologna
703/299-9766
gbologna@aasld.org
Press Room: November 13 – 17, 2015
Moscone West Convention Center, San Francisco, CA
Telephone: 415-348-4404

Researcher: Gregory Dore, PhD, MPH
Email: gdore@kirby.unsw.edu.au 
Phone: +61478486031

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. American Osteopathic Association Calls for Eliminating Unsolicited Requests to Purchase Medical Equipment
2. Malaria No More Honors Aleres Contributions to Diagnosing and Eliminating Malaria in sub-Saharan Africa
3. Germ-Eliminating Robot Tru-D SmartUVC Deployed at Catholic Medical Center
4. Tru-D SmartUVC to Showcase Germ-Eliminating UV Disinfection Robot at HealthTrust University Conference & Vendor Fair
5. Patients Report AcceleDent Improves Orthodontic Experience by Accelerating Treatment and Eliminating Pain
6. Several Market Access Barriers Impede Multinational Companies From Easily Accessing Argentinas Pharmaceutical Market But Attractive Opportunities Exist
7. Ansell Limited To Acquire BarrierSafe Solutions International
8. Video Remote Interpreting Removes Language Barriers at Catholic Health
9. AMCP Addiction Treatment Advisory Group to Identify Barriers, Improve Access to Treatment Services
10. Life After Failing TVM Treatments is a Rollercoaster of Side Effects for Women
11. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2019)... ... October 17, 2019 , ... The early detection of skin ... progresses further. With many patients first seeing a primary care doctor when physical ... skin cancer be extremely valuable. Enter technology company focused on finding cancer Lazarus. ...
(Date:10/11/2019)... LAGOS, Nigeria (PRWEB) , ... October 11, 2019 ... ... from Access Bank Plc, has announced plans for its 2019 'W' Health Month. ... women and their families by bridging the knowledge gap, providing access to health ...
(Date:10/11/2019)... ... ... MindShare Technology Founder and CEO Greg Povolny will offer his insights on using big ... Conference. The conference is at the Westin Indianapolis hotel in Indianapolis, IN with Povolny’s ... presentation will provide real world examples of how to apply complex analytics with a ...
Breaking Medicine Technology:
(Date:10/15/2019)... , ... October 14, 2019 , ... Khalieghya Dandie-Evans, a ... to ride atop the Donate Life Rose Parade® float in the 131st Rose Parade® ... and tissue donation across Northern California and Northern Nevada, the organization’s service area. , ...
(Date:10/15/2019)... , ... October 15, 2019 , ... Nashville Fertility Center ... the latest fertility doctor to join the practice. In addition to treating general infertility, ... (PCOS). , The team at NFC looks forward to Dr. Van Heertum joining the ...
(Date:10/10/2019)... ... October 10, 2019 , ... Santa Rosa ... services for the healthcare industry, has completed the first phase of a comprehensive ... Commonwealth of The Bahamas towards a fully integrated health information management system (iHIMS). ...
(Date:10/8/2019)... ... October 08, 2019 , ... SoCal Adolescent Wellness announces ... to announce the expansion of our services to better serve the families in Orange ... this last year to see the extraordinary impact this pre-intervention program has on the ...
(Date:10/8/2019)... ... October 08, 2019 , ... As a world-renowned expert using ... professor with the University of Maryland Department of Veterinary Medicine, continues to make ... Shi and his lab have discovered a new pathway by which liver macrophages ...
Breaking Medicine News(10 mins):